schliessen

Filtern

 

Bibliotheken

PRACTICE AND PROGRESS IN KIDNEY CANCER: METHODOLOGY FOR NOVEL DRUG DEVELOPMENT

The minimal efficacy of standard therapy for metastatic renal cell carcinoma (RCC) has resulted in the evaluation of numerous novel agents. Some agents have shown promise in phase II trials and yet none have improved survival over standard therapy in phase III trials. We examined existing data relev... Full description

Journal Title: The Journal of Urology 2004, Vol.171(6), pp.2115-2121
Main Author: Rini, Brian I
Other Authors: Weinberg, Vivian , Small, Eric J
Format: Electronic Article Electronic Article
Language: English
Subjects:
ID: ISSN: 0022-5347 ; E-ISSN: 1527-3792 ; DOI: 10.1097/01.ju.0000113728.46439.02
Link: https://www.sciencedirect.com/science/article/pii/S0022534705621143
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: elsevier_sdoi_10_1097_01_ju_0000113728_46439_02
title: PRACTICE AND PROGRESS IN KIDNEY CANCER: METHODOLOGY FOR NOVEL DRUG DEVELOPMENT
format: Article
creator:
  • Rini, Brian I
  • Weinberg, Vivian
  • Small, Eric J
subjects:
  • Kidney
  • Carcinoma
  • Renal Cell
  • Clinical Trials
  • Phase II
  • Clinical Trials
  • Phase III
  • Cytokines
  • Medicine
ispartof: The Journal of Urology, 2004, Vol.171(6), pp.2115-2121
description: The minimal efficacy of standard therapy for metastatic renal cell carcinoma (RCC) has resulted in the evaluation of numerous novel agents. Some agents have shown promise in phase II trials and yet none have improved survival over standard therapy in phase III trials. We examined existing data relevant to standard therapy and clinical trial methodology in RCC to understand patient, disease and trial design factors that have impacted clinical trial outcome and drug evaluation. Furthermore, we describe new paradigms for the evaluation of novel agents to optimize the yield of clinical research in RCC. A comprehensive review of published retrospective analyses and phase II/phase III trials in patients with metastatic RCC was undertaken. Publications with patient selection and/or therapeutic implications in our judgment are presented and evaluated. Patients with good performance status and access to centers with experienced staff may appropriately...
language: eng
source:
identifier: ISSN: 0022-5347 ; E-ISSN: 1527-3792 ; DOI: 10.1097/01.ju.0000113728.46439.02
fulltext: fulltext
issn:
  • 0022-5347
  • 00225347
  • 1527-3792
  • 15273792
url: Link


@attributes
ID341565711
RANK0.07
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
LOCALfalse
PrimoNMBib
record
control
sourcerecordiddoi_10_1097_01_ju_0000113728_46439_02
sourceidelsevier_s
recordidTN_elsevier_sdoi_10_1097_01_ju_0000113728_46439_02
sourcesystemPC
dbid
0--K
11B1
21P~
3457
44G.
57-5
6AAEDT
7AAQFI
8ADPAM
9AEVXI
10AGHFR
11AITUG
12ALXNB
13BELOY
14FDB
15FGOYB
16GBLVA
17KOM
18R2-
19RPZ
20SEL
21SES
22SSZ
23UV1
24XH2
pqid71900923
galeid196990609
display
typearticle
titlePRACTICE AND PROGRESS IN KIDNEY CANCER: METHODOLOGY FOR NOVEL DRUG DEVELOPMENT
creatorRini, Brian I ; Weinberg, Vivian ; Small, Eric J
ispartofThe Journal of Urology, 2004, Vol.171(6), pp.2115-2121
identifier
subjectKidney ; Carcinoma ; Renal Cell ; Clinical Trials ; Phase II ; Clinical Trials ; Phase III ; Cytokines ; Medicine
descriptionThe minimal efficacy of standard therapy for metastatic renal cell carcinoma (RCC) has resulted in the evaluation of numerous novel agents. Some agents have shown promise in phase II trials and yet none have improved survival over standard therapy in phase III trials. We examined existing data relevant to standard therapy and clinical trial methodology in RCC to understand patient, disease and trial design factors that have impacted clinical trial outcome and drug evaluation. Furthermore, we describe new paradigms for the evaluation of novel agents to optimize the yield of clinical research in RCC. A comprehensive review of published retrospective analyses and phase II/phase III trials in patients with metastatic RCC was undertaken. Publications with patient selection and/or therapeutic implications in our judgment are presented and evaluated. Patients with good performance status and access to centers with experienced staff may appropriately...
languageeng
source
version5
lds50peer_reviewed
links
openurl$$Topenurl_article
openurlfulltext$$Topenurlfull_article
backlink$$Uhttps://www.sciencedirect.com/science/article/pii/S0022534705621143$$EView_record_in_ScienceDirect_(Access_to_full_text_may_be_restricted)
search
creatorcontrib
0Rini, Brian I
1Weinberg, Vivian
2Small, Eric J
titlePRACTICE AND PROGRESS IN KIDNEY CANCER: METHODOLOGY FOR NOVEL DRUG DEVELOPMENT
description

The minimal efficacy of standard therapy for metastatic renal cell carcinoma (RCC) has resulted in the evaluation of numerous novel agents. Some agents have shown promise in phase II trials and yet none have improved survival over standard therapy in phase III trials. We examined existing data relevant to standard therapy and clinical trial methodology in RCC to understand patient, disease and trial design factors that have impacted clinical trial outcome and drug evaluation. Furthermore, we describe new paradigms for the evaluation of novel agents to optimize the yield of clinical research in RCC.

A comprehensive review of published retrospective analyses and phase II/phase III trials in patients with metastatic RCC was undertaken. Publications with patient selection and/or therapeutic implications in our judgment are presented and evaluated.

Patients with good performance status and access to centers with experienced staff may appropriately...

subject
0Kidney
1Carcinoma
2Renal Cell
3Clinical Trials
4Phase II
5Phase III
6Cytokines
7Medicine
general
0English
1Elsevier Inc
210.1097/01.ju.0000113728.46439.02
3ScienceDirect (Elsevier)
4ScienceDirect Journals (Elsevier)
sourceidelsevier_s
recordidelsevier_sdoi_10_1097_01_ju_0000113728_46439_02
issn
00022-5347
100225347
21527-3792
315273792
rsrctypearticle
creationdate2004
addtitleThe Journal of Urology
searchscope
0elsevier_full
1elsevier2
scope
0elsevier_full
1elsevier2
lsr44$$EView_record_in_ScienceDirect_(Access_to_full_text_may_be_restricted)
tmp01ScienceDirect Journals (Elsevier)
tmp02
0--K
11B1
21P~
3457
44G.
57-5
6AAEDT
7AAQFI
8ADPAM
9AEVXI
10AGHFR
11AITUG
12ALXNB
13BELOY
14FDB
15FGOYB
16GBLVA
17KOM
18R2-
19RPZ
20SEL
21SES
22SSZ
23UV1
24XH2
startdate20040101
enddate20041231
lsr40The Journal of Urology, 2004, Vol.171 (6), pp.2115-2121
doi10.1097/01.ju.0000113728.46439.02
citationpf 2115 pt 2121 vol 171 issue 6
lsr30VSR-Enriched:[pqid, galeid]
sort
titlePRACTICE AND PROGRESS IN KIDNEY CANCER: METHODOLOGY FOR NOVEL DRUG DEVELOPMENT
authorRini, Brian I ; Weinberg, Vivian ; Small, Eric J
creationdate20040000
lso0120040000
facets
frbrgroupid4863040949533045756
frbrtype5
newrecords20190904
languageeng
topic
0Kidney
1Carcinoma
2Renal Cell
3Clinical Trials
4Phase II
5Phase III
6Cytokines
7Medicine
collectionScienceDirect (Elsevier)
prefilterarticles
rsrctypearticles
creatorcontrib
0Rini, Brian I
1Weinberg, Vivian
2Small, Eric J
jtitleJournal of Urology
creationdate2004
toplevelpeer_reviewed
delivery
delcategoryRemote Search Resource
fulltextfulltext
addata
aulast
0Rini
1Weinberg
2Small
aufirst
0Brian I
1Vivian
2Eric J
auinitB
auinit1B
au
0Rini, Brian I
1Weinberg, Vivian
2Small, Eric J
atitlePRACTICE AND PROGRESS IN KIDNEY CANCER: METHODOLOGY FOR NOVEL DRUG DEVELOPMENT
jtitleThe Journal of Urology
date2004
risdate2004
volume171
issue6
spage2115
epage2121
pages2115-2121
issn0022-5347
eissn1527-3792
formatjournal
genrearticle
ristypeJOUR
abstract

The minimal efficacy of standard therapy for metastatic renal cell carcinoma (RCC) has resulted in the evaluation of numerous novel agents. Some agents have shown promise in phase II trials and yet none have improved survival over standard therapy in phase III trials. We examined existing data relevant to standard therapy and clinical trial methodology in RCC to understand patient, disease and trial design factors that have impacted clinical trial outcome and drug evaluation. Furthermore, we describe new paradigms for the evaluation of novel agents to optimize the yield of clinical research in RCC.

A comprehensive review of published retrospective analyses and phase II/phase III trials in patients with metastatic RCC was undertaken. Publications with patient selection and/or therapeutic implications in our judgment are presented and evaluated.

Patients with good performance status and access to centers with experienced staff may appropriately...

pubElsevier Inc
doi10.1097/01.ju.0000113728.46439.02
lad01The Journal of Urology